查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1968071

全球抗体药物复合体契约製造市场规模、份额、趋势和成长分析报告（2026-2034）

Global Antibody Drug Conjugates Contract Manufacturing Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 113 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

抗体药物复合体(ADC)契约製造市场预计将从 2025 年的 103.7 亿美元成长到 2034 年的 274.5 亿美元，2026 年至 2034 年的复合年增长率为 11.42%。

随着抗体药物复合体（ADC）作为一种创新癌症治疗方法的出现，全球抗体药物复合体合约契约製造市场正在迅速扩张。製药公司越来越多地将复杂的生产流程外包，包括单株抗体、细胞毒性有效载荷和连接子技术。 ADC生产相关的技术复杂性和高额资金需求，正在强化全球专业契约製造公司的角色。

推动成长的主要因素包括不断扩充的肿瘤治疗产品线、癌症发生率的上升以及抗体偶联药物（ADC）疗法监管核准的增加。偶联技术和标靶药物递送机制的进步正在提升治疗效果和安全性。此外，生物製药公司正在寻求灵活的生产模式，以有效地完成从临床到商业规模的过渡，从而催生了对整合式合约研发生产（CDMO）服务的强劲需求。

随着新一代抗体偶联药物（ADC）的适应症扩大至肿瘤以外的更广泛领域，其未来前景仍十分光明。持续投资于高等级生物安全设施和先进的生物製程能力将助力市场扩张。策略联盟和併购将强化服务组合，确保ADC契约製造产业持续成为精准医疗创新不可或缺的基石。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

  • 市场谱系展望
  • 渗透率和成长前景分析
  • 价值链分析
  • 法律规范
    • 标准与合规性
    • 监管影响分析
  • 市场动态
    • 市场驱动因素
    • 市场限制因素
    • 市场机会
    • 市场挑战
  • 波特五力分析
  • PESTLE分析

第四章：全球抗体药物复合体契约製造市场：依条件划分

  • 市场分析、洞察与预测
  • 多发性骨髓瘤
  • 淋巴瘤
  • 乳癌
  • 其他的

第五章：全球抗体药物复合体契约製造市场：依连接子分类

  • 市场分析、洞察与预测
  • 可切割连接器
  • 不可切割的连接子

第六章 全球抗体药物复合体契约製造市场：按地区划分

  • 区域分析
  • 北美市场分析、洞察与预测
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲市场分析、洞察与预测
    • 英国
    • 法国
    • 德国
    • 义大利
    • 俄罗斯
    • 其他欧洲国家
  • 亚太市场分析、洞察与预测
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 东南亚
    • 其他亚太国家
  • 拉丁美洲市场分析、洞察与预测
    • 巴西
    • 阿根廷
    • 秘鲁
    • 智利
    • 其他拉丁美洲国家
  • 中东和非洲市场分析、洞察与预测
    • 沙乌地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中东和非洲国家

第七章 竞争情势

  • 最新趋势
  • 公司分类
  • 供应链和销售管道合作伙伴（根据现有资讯）
  • 市场占有率和市场定位分析（基于现有资讯）
  • 供应商情况（基于现有资讯）
  • 策略规划

第八章：公司简介

  • 主要公司的市占率分析
  • 公司简介
    • Sterling
    • Recipharm AB
    • Lonza
    • Catalent Inc
    • Sartorius AG
    • Wuxi Biologics
    • Samsung Biologics
    • Piramal Group（Piramal Pharma Solutions）
    • AbbVie Inc.（AbbVie Contract Manufacturing）
    • Merck KGaA
简介目录
Product Code: VMR112110154

The Antibody Drug Conjugates Contract Manufacturing Market size is expected to reach USD 27.45 Billion in 2034 from USD 10.37 Billion (2025) growing at a CAGR of 11.42% during 2026-2034.

The Global Antibody Drug Conjugates Contract Manufacturing Market is expanding rapidly as ADCs emerge as a transformative oncology treatment modality. Pharmaceutical companies are increasingly outsourcing complex manufacturing processes involving monoclonal antibodies, cytotoxic payloads, and linker technologies. The technical intricacies and high capital requirements associated with ADC production have strengthened the role of specialized contract manufacturers worldwide.

Growth is primarily driven by the expanding oncology pipeline, rising cancer prevalence, and increasing regulatory approvals for ADC therapies. Advances in conjugation technologies and targeted drug delivery mechanisms have improved therapeutic efficacy and safety profiles. Additionally, biopharma firms are seeking flexible production models to manage clinical-to-commercial scale transitions efficiently, creating strong demand for integrated CDMO services.

Future prospects remain highly promising as next-generation ADCs target broader indications beyond oncology. Continuous investments in high-containment facilities and advanced bioprocessing capabilities will support market expansion. Strategic collaborations and mergers are expected to enhance service portfolios, ensuring the ADC contract manufacturing sector remains a critical backbone of precision medicine innovation.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Condition

  • Myeloma
  • Lymphoma
  • Breast Cancer
  • Others

By Linker

  • Cleavable Linker
  • Non-cleavable Linker

COMPANIES PROFILED

  • Sterling, Recipharm AB, Lonza, Catalent Inc, Sartorius AG, Wuxi Biologics, Samsung Biologics, Piramal Group Piramal Pharma Solutions, AbbVie Inc AbbVie Contract Manufacturing, Merck KGaA
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET: BY CONDITION 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Condition
  • 4.2. Myeloma Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Lymphoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Breast Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET: BY LINKER 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Linker
  • 5.2. Cleavable Linker Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Non-cleavable Linker Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET: BY REGION 2022-2034(USD MN)

  • 6.1. Regional Outlook
  • 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.2.1 By Condition
    • 6.2.2 By Linker
    • 6.2.3 United States
    • 6.2.4 Canada
    • 6.2.5 Mexico
  • 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.3.1 By Condition
    • 6.3.2 By Linker
    • 6.3.3 United Kingdom
    • 6.3.4 France
    • 6.3.5 Germany
    • 6.3.6 Italy
    • 6.3.7 Russia
    • 6.3.8 Rest Of Europe
  • 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.4.1 By Condition
    • 6.4.2 By Linker
    • 6.4.3 India
    • 6.4.4 Japan
    • 6.4.5 South Korea
    • 6.4.6 Australia
    • 6.4.7 South East Asia
    • 6.4.8 Rest Of Asia Pacific
  • 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.5.1 By Condition
    • 6.5.2 By Linker
    • 6.5.3 Brazil
    • 6.5.4 Argentina
    • 6.5.5 Peru
    • 6.5.6 Chile
    • 6.5.7 South East Asia
    • 6.5.8 Rest of Latin America
  • 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.6.1 By Condition
    • 6.6.2 By Linker
    • 6.6.3 Saudi Arabia
    • 6.6.4 UAE
    • 6.6.5 Israel
    • 6.6.6 South Africa
    • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

  • 7.1. Recent Developments
  • 7.2. Company Categorization
  • 7.3. Supply Chain & Channel Partners (based on availability)
  • 7.4. Market Share & Positioning Analysis (based on availability)
  • 7.5. Vendor Landscape (based on availability)
  • 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING INDUSTRY

  • 8.1. Top Companies Market Share Analysis
  • 8.2. Company Profiles
    • 8.2.1 Sterling
    • 8.2.2 Recipharm AB
    • 8.2.3 Lonza
    • 8.2.4 Catalent Inc
    • 8.2.5 Sartorius AG
    • 8.2.6 Wuxi Biologics
    • 8.2.7 Samsung Biologics
    • 8.2.8 Piramal Group (Piramal Pharma Solutions)
    • 8.2.9 AbbVie Inc. (AbbVie Contract Manufacturing)
    • 8.2.10 Merck KGaA